Drospirenone And Ethinyl Estradiol Kit
Product Images NDC 31722-945

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Drospirenone And Ethinyl Estradiol (NDC 31722-945). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

3blistercarton (3sblistercarton)

This is a description for a package of oral contraceptive tablets containing Drospirenone and Ethinyl Estradiol, with 3 blister cards of 28 tablets each. The tablets are meant to prevent pregnancy and contain 3 mg/0.03 mg of the active ingredients. The package includes information for dispensers, and it is stated that the product does not protect against HIV and other sexually transmitted diseases. The National Drug Code (NDC) is 31722-945-31.*

FDA Label Image

Camber (Camber)

FDA Label Image

Camber2 (Camber2)

FDA Label Image

Drosandeedosechart (Drosandeedosechart)

This is a chart outlining various forms of birth control and their effectiveness. The text lists different categories, such as "Fewer than 1 pregnancy per 100 women in one year" and "85 or more pregnancies per 100 women in one year," and then lists types of birth control methods under each category. The effectiveness of each method varies, with some methods having a higher rate of pregnancy prevention than others. The chart includes options such as sterilization, birth control pills, condoms, and natural family planning methods such as avoiding sex during the most fertile days of the cycle.*

FDA Label Image

Drosandeefig-1 (Drosandeefig 1)

FDA Label Image

Drosandeefig-2 (Drosandeefig 2)

This text presents different ranges of the number of non-pregnant women with and without the use of Combined Oral Contraceptives (COC). It also shows the range for postpartum women up to 12 weeks. Additionally, it provides the number of women with blood clots out of 10,000 Women Years (WY). Lastly, it mentions the actual pregnancy duration used in the reference studies and the rate of blood clots per 10,000 WY based on a model assumption that pregnancy duration is nine months.*

FDA Label Image

Drospandeebloodclot (Drospandeebloodclot)

FDA Label Image

Drospstructure (Drospstructure)

FDA Label Image

Eestructure (Eestructure)

FDA Label Image

Foil (Foil)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.